State-Specific Hepatitis C Virus Clearance Cascades - United States, 2013-2022

被引:0
|
作者
Tsang, Clarisse A. [1 ]
Tonzel, Julius [1 ,2 ]
Symum, Hasan [1 ]
Kaufman, Harvey W. [3 ]
William, A. Meyer, III [3 ]
Osinubi, Ademola [1 ,3 ]
Thompson, William W. [1 ]
Wester, Carolyn [1 ]
机构
[1] CDC, Div Viral Hepatitis, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, Atlanta, GA 30322 USA
[2] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol, New Orleans, LA USA
[3] Quest Diagnost, Secaucus, NJ USA
来源
MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT | 2024年 / 73卷 / 21期
关键词
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Hepatitis C is a deadly, yet curable, disease. National hepatitis C elimination goals for 2030 call for at least 80% of persons with hepatitis C to achieve viral clearance. A welltolerated treatment results in sustained viral clearance in >= 95% of cases. Hepatitis C virus (HCV) clearance cascades characterize a sequence of steps that follow the progression from testing to sustained viral clearance. Monitoring HCV clearance cascades is important for tracking progress toward elimination goals and identifying gaps in diagnosis, treatment, and prevention. State-specific HCV clearance cascades based on laboratory results were developed using longitudinal data from a large national, commercial laboratory during January 1, 2013-December 31, 2022. State-level estimates of viral testing among persons with evidence of past or current HCV infection ranged from 51% (Hawaii) to 99% (South Dakota), and hepatitis C viral clearance among persons with diagnosed HCV infection ranged from 10% (West Virginia) to 51% (Connecticut). These are the first state-level estimates using CDC guidance and data from a large commercial laboratory with national coverage to generate HCV clearance cascades. These estimates reveal substantial gaps in hepatitis C diagnosis, treatment, and prevention and can help guide prioritization of activities and resources to achieve hepatitis C elimination goals.
引用
收藏
页码:495 / 500
页数:6
相关论文
共 50 条
  • [21] Increase in Hepatitis A Virus Infections - United States, 2013-2018
    Foster, Monique A.
    Hofmeister, Megan G.
    Kupronis, Benjamin A.
    Lin, Yulin
    Xia, Guo-Liang
    Yin, Shaoman
    Teshale, Eyasu
    MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT, 2019, 68 (18): : 413 - 415
  • [23] OBTAINING STATE-SPECIFIC COSTS FOR ECONOMIC MODELLING IN HEPATITIS C: A RETROSPECTIVE COSTING STUDY
    Haines, Alexander
    Yao, Zhan
    Thein, Hla Hla
    Wong, William W. L.
    Krahn, Murray D.
    MEDICAL DECISION MAKING, 2020, 40 (01) : E2 - E3
  • [24] Infection with hepatitis C virus genotype 4 in the United States
    Lyra, AC
    Ramrakhiani, S
    Bacon, BR
    Di Bisceglie, AM
    JOURNAL OF CLINICAL GASTROENTEROLOGY, 2004, 38 (01) : 68 - 71
  • [25] Changes in State-Specific Childhood Obesity and Overweight Prevalence in the United States From 2003 to 2007
    Singh, Gopal K.
    Kogan, Michael D.
    van Dyck, Peter C.
    ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE, 2010, 164 (07): : 598 - 607
  • [26] Hepatitis C virus infection in United States correctional institutions
    Frederick L. Altice
    R. Douglas Bruce
    Current Hepatitis Reports, 2004, 3 (3) : 112 - 118
  • [28] Testing for Hepatitis C Virus Infection Among Adults Aged ≥18 in the United States, 2013-2017
    King, Hope
    Soh, J. E.
    Thompson, William W.
    Brown, Jessica Rogers
    Rapposelli, Karina
    Vellozzi, Claudia
    PUBLIC HEALTH REPORTS, 2022, 137 (06) : 1107 - 1117
  • [29] Trends in the Prevalence of Hepatitis C Virus Infection based on the Insurance Status in the United States from 2013 to 2018
    Kim, Donghee
    Cholankeril, George
    Dennis, Brittany B.
    Alshuwaykh, Omar
    Kumari, Radhika
    Wong, Robert J.
    Ahmed, Aijaz
    LIVER INTERNATIONAL, 2022, 42 (02) : 340 - 349
  • [30] External Coercion, Internal Accommodation: China's Wedge Strategies Towards the Vietnam-United States Partnership, 2013-2022
    Vu, Khang X.
    JOURNAL OF CONTEMPORARY CHINA, 2024, 33 (149) : 850 - 870